Human blood cell levels of 5-hydroxymethylcytosine (5hmC) decline with age, partly related to acquired mutations in TET2

Experimental Hematology

Volumn 44, Issue 11, 2016, Pages 1072-1084

  Buscarlet, Manuel ^a   Tessier, Alain ^b   Provost, Sylvie ^c   Mollica, Luigina ^a,d,e   Busque, Lambert ^a,d,e  

^a Research Centre   (Canada)

^b Dept of Electrical and Computer Engineering   (Canada)

^c MONTREAL HEART INSTITUTE   (Canada)

^d MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; WT1 PROTEIN; 5-HYDROXYMETHYLCYTOSINE; BIOLOGICAL MARKER; DNA BINDING PROTEIN; ONCOPROTEIN; TET2 PROTEIN, HUMAN;

AGE DISTRIBUTION; AGED; AGING; ARTICLE; ASXL1 GENE; CELL LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DNMT3A GENE; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; FRAMESHIFT MUTATION; GENE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IDH1 GENE; IDH2 GENE; LIQUID CHROMATOGRAPHY; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NEWBORN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; SEQUENCE ANALYSIS; TELOMERE LENGTH; TET2 GENE; VERY ELDERLY; WT1 GENE; X CHROMOSOME INACTIVATION; AGE; BLOOD CELL; GENETICS; MASS SPECTROMETRY; METABOLISM; METABOLOMICS; MUTATION; MYELOID LEUKEMIA; PROCEDURES;

5-METHYLCYTOSINE; AGE FACTORS; AGED; AGED, 80 AND OVER; BIOMARKERS; BLOOD CELLS; CHROMATOGRAPHY, LIQUID; DNA-BINDING PROTEINS; HUMANS; LEUKEMIA, MYELOID; MASS SPECTROMETRY; METABOLOMICS; MUTATION; PROTO-ONCOGENE PROTEINS;

EID: 84992660393     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2016.07.009     Document Type: Article

References (88)

1. 1 Busque, L., Mio, R., Mattioli, J., et al. Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. Blood 88 (1996), 59–65.
2. 2 Gale, R.E., Fielding, A.K., Harrison, C.N., Linch, D.C., Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age. Br J Haematol 98 (1997), 512–519.
3. 3 Champion, K.M., Gilbert, J.G., Asimakopoulos, F.A., Hinshelwood, S., Green, A.R., Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes. Br J Haematol 97 (1997), 920–926.
4. 4 Busque, L., Patel, J.P., Figueroa, M.E., et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 44 (2012), 1179–1181.
5. 5 Forsberg, L.A., Rasi, C., Razzaghian, H.R., et al. Age-related somatic structural changes in the nuclear genome of human blood cells. Am J Hum Genet 90 (2012), 217–228.
6. 6 Laurie, C.C., Laurie, C.A., Rice, K., et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet 44 (2012), 642–650.
7. 7 Jacobs, K.B., Yeager, M., Zhou, W., et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet 44 (2012), 651–658.
8. 8 Xie, M., Lu, C., Wang, J., et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 20 (2014), 1472–1478.
9. 9 Genovese, G., Kähler, A.K., Handsaker, R.E., et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371 (2014), 2477–2487.
10. 10 Jaiswal, S., Fontanillas, P., Flannick, J., et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371 (2014), 2488–2498.
11. 11 Madzo, J., Liu, H., Rodriguez, A., et al. Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythropoiesis. Cell Rep 6 (2014), 231–244.
12. 12 Eriksson, A., Lennartsson, A., Lehmann, S., Epigenetic aberrations in acute myeloid leukemia: early key events during leukemogenesis. Exp Hematol 43 (2015), 609–624.
13. 13 Shih, A.H., Jiang, Y., Meydan, C., et al. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell 27 (2015), 502–515.
14. 14 Razin, A., Riggs, A.D., DNA methylation and gene function. Science 210 (1980), 604–610.
15. 15 Jaenisch, R., Bird, A., Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 33 (2003), 245–254.
16. 16 Hannum, G., Guinney, J., Zhao, L., et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol Cell 49 (2013), 359–367.
17. 17 Sun, D., Luo, M., Jeong, M., et al. Epigenomic profiling of young and aged HSCs reveals concerted changes during aging that reinforce self-renewal. Cell Stem Cell 14 (2014), 673–688.
18. 18 Beerman, I., Rossi, D.J., Epigenetic control of stem cell potential during homeostasis, aging, and disease. Cell Stem Cell 16 (2015), 613–625.
19. 19 Scourzic, L., Mouly, E., Bernard, O.A., TET proteins and the control of cytosine demethylation in cancer. Genome Med, 7, 2015, 9.
20. 20 Ko, M., Huang, Y., Jankowska, A.M., et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468 (2010), 839–843.
21. 21 Tahiliani, M., Koh, K.P., Shen, Y., et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324 (2009), 930–935.
22. 22 Kriaucionis, S., Heintz, N., The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 324 (2009), 929–930.
23. 23 Wu, H., Zhang, Y., Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes Dev 25 (2011), 2436–2452.
24. 24 Kroeze, L.I., Aslanyan, M.G., van Rooij, A., et al. Characterization of acute myeloid leukemia based on levels of global hydroxymethylation. Blood 124 (2014), 1110–1118.
25. 25 Liu, X., Zhang, G., Yi, Y., et al. Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes. Leuk Lymphoma 54 (2013), 2466–2473.
26. 26 Lian, C.G., Xu, Y., Ceol, C., et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 150 (2012), 1135–1146.
27. 27 Ahn, J.S., Kim, H.J., Kim, Y.K., et al. Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype. Haematologica 100 (2015), e351–e353.
28. 28 Orr, B.A., Haffner, M.C., Nelson, W.G., Yegnasubramanian, S., Eberhart, C.G., Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. PLoS One, 7, 2012, e41036.
29. 29 Larson, A.R., Dresser, K.A., Zhan, Q., et al. Loss of 5-hydroxymethylcytosine correlates with increasing morphologic dysplasia in melanocytic tumors. Mod Pathol 27 (2014), 936–944.
30. 30 Jäwert, F., Hasséus, B., Kjeller, G., Magnusson, B., Sand, L., Larsson, L., Loss of 5-hydroxymethylcytosine and TET2 in oral squamous cell carcinoma. Anticancer Res 33 (2013), 4325–4328.
31. 31 Gambichler, T., Sand, M., Skrygan, M., Loss of 5-hydroxymethylcytosine and ten-eleven translocation 2 protein expression in malignant melanoma. Melanoma Res 23 (2013), 218–220.
32. 32 Kudo, Y., Tateishi, K., Yamamoto, K., et al. Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci 103 (2012), 670–676.
33. 33 Globisch, D., Münzel, M., Müller, M., et al. Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. PLoS One, 5, 2010, e15367.
34. 34 Guo, J.U., Szulwach, K.E., Su, Y., et al. Genome-wide antagonism between 5-hydroxymethylcytosine and DNA methylation in the adult mouse brain. Front Biol (Beijing) 9 (2014), 66–74.
35. 35 Wang, T., Pan, Q., Lin, L., et al. Genome-wide DNA hydroxymethylation changes are associated with neurodevelopmental genes in the developing human cerebellum. Hum Mol Genet 21 (2012), 5500–5510.
36. 36 Chen, H., Dzitoyeva, S., Manev, H., Effect of aging on 5-hydroxymethylcytosine in the mouse hippocampus. Restor Neurol Neurosci 30 (2012), 237–245.
37. 37 Sherwani, S.I., Khan, H.A., Role of 5-hydroxymethylcytosine in neurodegeneration. Gene 570 (2015), 17–24.
38. 38 Figueroa-Romero, C., Hur, J., Bender, D.E., et al. Identification of epigenetically altered genes in sporadic amyotrophic lateral sclerosis. PLoS One, 7, 2012, e52672.
39. 39 Coppieters, N., Dieriks, B.V., Lill, C., Faull, R.L., Curtis, M.A., Dragunow, M., Global changes in DNA methylation and hydroxymethylation in Alzheimer's disease human brain. Neurobiol Aging 35 (2014), 1334–1344.
40. 40 Bradley-Whitman, M.A., Lovell, M.A., Epigenetic changes in the progression of Alzheimer's disease. Mech Ageing Dev 134 (2013), 486–495.
41. 41 Szulwach, K.E., Li, X., Li, Y., et al. 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat Neurosci 14 (2011), 1607–1616.
42. 42 Cheng, Y., Bernstein, A., Chen, D., Jin, P., 5-Hydroxymethylcytosine: a new player in brain disorders?. Exp Neurol 268 (2015), 3–9.
43. 43 Dong, E., Gavin, D.P., Chen, Y., Davis, J., Upregulation of TET1 and downregulation of APOBEC3A and APOBEC3C in the parietal cortex of psychotic patients. Transl Psychiatry, 2, 2012, e159.
44. 44 Boks, M.P., Derks, E.M., Weisenberger, D.J., et al. The relationship of DNA methylation with age, gender and genotype in twins and healthy controls. PLoS One, 4, 2009, e6767.
45. 45 Fraga, M.F., Ballestar, E., Paz, M.F., et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A 102 (2005), 10604–10609.
46. 46 Issa, J.P., Aging and epigenetic drift: a vicious cycle. J Clin Invest 124 (2014), 24–29.
47. 47 Shen, H., Laird, P.W., Interplay between the cancer genome and epigenome. Cell 153 (2013), 38–55.
48. 48 Chowdhury, B., Cho, I.H., Hahn, N., Irudayaraj, J., Quantification of 5-methylcytosine, 5-hydroxymethylcytosine and 5-carboxylcytosine from the blood of cancer patients by an enzyme-based immunoassay. Anal Chim Acta 852 (2014), 212–217.
49. 49 Nestor, C.E., Ottaviano, R., Reddington, J., et al. Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes. Genome Res 22 (2012), 467–477.
50. 50 Kraus, T.F., Guibourt, V., Kretzschmar, H.A., 5-Hydroxymethylcytosine, the “Sixth Base”, during brain development and ageing. J Neural Transm (Vienna) 122 (2015), 1035–1043.
51. 51 Ficz, G., Branco, M.R., Seisenberger, S., et al. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature 473 (2011), 398–402.
52. 52 Szwagierczak, A., Bultmann, S., Schmidt, C.S., Spada, F., Leonhardt, H., Sensitive enzymatic quantification of 5-hydroxymethylcytosine in genomic DNA. Nucleic Acids Res, 38, 2010, e181.
53. 53 Shahal, T., Gilat, N., Michaeli, Y., Redy-Keisar, O., Shabat, D., Ebenstein, Y., Spectroscopic quantification of 5-hydroxymethylcytosine in genomic DNA. Anal Chem 86 (2014), 8231–8237.
54. 54 Song, C.X., Szulwach, K.E., Fu, Y., et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol 29 (2011), 68–72.
55. 55 Yu, M., Hon, G.C., Szulwach, K.E., et al. Base-resolution analysis of 5-hydroxymethylcytosine in the mammalian genome. Cell 149 (2012), 1368–1380.
56. 56 Gao, F., Xia, Y., Hydroxymethylation- and methylation-sensitive tag sequencing: how will this technology change clinical applications of DNA methylation profiling?. Epigenomics 5 (2013), 355–357.
57. 57 Booth, M.J., Branco, M.R., Ficz, G., et al. Quantitative sequencing of 5-methylcytosine and 5-hydroxymethylcytosine at single-base resolution. Science 336 (2012), 934–937.
58. 58 Song, L., James, S.R., Kazim, L., Karpf, A.R., Specific method for the determination of genomic DNA methylation by liquid chromatography-electrospray ionization tandem mass spectrometry. Anal Chem 77 (2005), 504–510.
59. 59 Tsuji, M., Matsunaga, H., Jinno, D., Tsukamoto, H., Suzuki, N., Tomioka, Y., A validated quantitative liquid chromatography-tandem quadrupole mass spectrometry method for monitoring isotopologues to evaluate global modified cytosine ratios in genomic DNA. J Chromatogr B Analyt Technol Biomed Life Sci 953–954 (2014), 38–47.
60. 60 Shen, L., Zhang, Y., Enzymatic analysis of Tet proteins: key enzymes in the metabolism of DNA methylation. Methods Enzymol 512 (2012), 93–105.
61. 61 Yin, R., Mo, J., Lu, M., Wang, H., Detection of human urinary 5-hydroxymethylcytosine by stable isotope dilution HPLC-MS/MS analysis. Anal Chem 87 (2015), 1846–1852.
62. 62 Hu, C.W., Chen, J.L., Hsu, Y.W., Yen, C.C., Chao, M.R., Trace analysis of methylated and hydroxymethylated cytosines in DNA by isotope-dilution LC-MS/MS: first evidence of DNA methylation in Caenorhabditis elegans. Biochem J 465 (2015), 39–47.
63. 63 Le, T., Kim, K.P., Fan, G., Faull, K.F., A sensitive mass spectrometry method for simultaneous quantification of DNA methylation and hydroxymethylation levels in biological samples. Anal Biochem 412 (2011), 203–209.
64. 64 Bolduc, V., Chagnon, P., Provost, S., et al. No evidence that skewing of X chromosome inactivation patterns is transmitted to offspring in humans. J Clin Invest 118 (2008), 333–341.
65. 65 Cawthon, R.M., Telomere measurement by quantitative PCR. Nucleic Acids Res, 30, 2002, e47.
66. 66 Mollica, L., Fleury, I., Belisle, C., Provost, S., Roy, D.C., Busque, L., No association between telomere length and blood cell counts in elderly individuals. J Gerontol A Biol Sci Med Sci 64 (2009), 965–967.
67. 67 López-Otín, C., Blasco, M.A., Partridge, L., Serrano, M., Kroemer, G., The hallmarks of aging. Cell 153 (2013), 1194–1217.
68. 68 Johansson, A., Enroth, S., Gyllensten, U., Continuous aging of the human DNA methylome throughout the human lifespan. PLoS One, 8, 2013, e67378.
69. 69 Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
70. 70 Hanahan, D., Weinberg, R.A., The hallmarks of cancer. Cell 100 (2000), 57–70.
71. 71 Ito, S., Shen, L., Dai, Q., et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333 (2011), 1300–1303.
72. 72 Fuke, C., Shimabukuro, M., Petronis, A., et al. Age related changes in 5-methylcytosine content in human peripheral leukocytes and placentas: an HPLC-based study. Ann Hum Genet 68 (2004), 196–204.
73. 73 Taiwo, O., Wilson, G.A., Emmett, W., et al. DNA methylation analysis of murine hematopoietic side population cells during aging. Epigenetics 8 (2013), 1114–1122.
74. 74 Maegawa, S., Hinkal, G., Kim, H.S., et al. Widespread and tissue specific age-related DNA methylation changes in mice. Genome Res 20 (2010), 332–340.
75. 75 Heyn, H., Li, N., Ferreira, H.J., et al. Distinct DNA methylomes of newborns and centenarians. Proc Natl Acad Sci U S A 109 (2012), 10522–10527.
76. 76 Sedivy, J.M., Banumathy, G., Adams, P.D., Aging by epigenetics–a consequence of chromatin damage?. Exp Cell Res 314 (2008), 1909–1917.
77. 77 Gonzalo, S., Epigenetic alterations in aging. J Appl Physiol (1985) 109 (2010), 586–597.
78. 78 Wilson, V.L., Smith, R.A., Ma, S., Cutler, R.G., Genomic 5-methyldeoxycytidine decreases with age. J Biol Chem 262 (1987), 9948–9951.
79. 79 Kim, S.J., Zhao, H., Hardikar, S., Singh, A.K., Goodell, M.A., Chen, T., A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells. Blood 122 (2013), 4086–4089.
80. 80 Russler-Germain, D.A., Spencer, D.H., Young, M.A., et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell 25 (2014), 442–454.
81. 81 Schoofs, T., Berdel, W.E., Müller-Tidow, C., Origins of aberrant DNA methylation in acute myeloid leukemia. Leukemia 28 (2014), 1–14.
82. 82 Busque, L., Gilliland, D.G., X-inactivation analysis in the 1990s: promise and potential problems. Leukemia 12 (1998), 128–135.
83. 83 Bernard, L., Belisle, C., Mollica, L., et al. Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms. Leukemia 23 (2009), 287–291.
84. 84 Terasaki, Y., Okumura, H., Ohtake, S., Nakao, S., Accelerated telomere length shortening in granulocytes: a diagnostic marker for myeloproliferative diseases. Exp Hematol 30 (2002), 1399–1404.
85. 85 Ruella, M., Salmoiraghi, S., Risso, A., et al. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy. Exp Hematol 41 (2013), 627–634.
86. 86 Hastie, N.D., Dempster, M., Dunlop, M.G., Thompson, A.M., Green, D.K., Allshire, R.C., Telomere reduction in human colorectal carcinoma and with ageing. Nature 346 (1990), 866–868.
87. 87 Hornsby, P.J., Short telomeres: cause or consequence of aging?. Aging Cell 5 (2006), 577–578.
88. 88 Beerman, I., Bock, C., Garrison, B.S., et al. Proliferation-dependent alterations of the DNA methylation landscape underlie hematopoietic stem cell aging. Cell Stem Cell 12 (2013), 413–425.